These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32346433)

  • 1. Efficacy of ranibizumab combined with photodynamic therapy on wet age-related macular degeneration.
    Chen L; Wang B; Cui W; Fang S
    Exp Ther Med; 2020 Jun; 19(6):3691-3697. PubMed ID: 32346433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of one-year results of photodynamic therapy combined with ranibizumab or aflibercept for treating polypoidal choroidal vasculopathy.
    Ito A; Maruyama-Inoue M; Kitajima Y; Sato S; Inoue T; Yamane S; Kadonosono K
    PLoS One; 2020; 15(6):e0235213. PubMed ID: 32579608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
    Spielberg L; Leys A
    Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Intravitreal ranibizumab in combination with verteporfin photodynamic therapy in neovascular macular degeneration].
    Soucek P; Soucková I
    Cesk Slov Oftalmol; 2008 Jul; 64(4):135-40. PubMed ID: 18780651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Optical Coherence Tomography Angiography-based Follow-up Observation of Wet Age-related Macular Degeneration after Intravitreal Anti-Ranibizumab Therapy].
    Yuan MZ; Zhou HY; Chen YX
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Jun; 41(3):359-366. PubMed ID: 31282330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis.
    Ba J; Peng RS; Xu D; Li YH; Shi H; Wang Q; Yu J
    Drug Des Devel Ther; 2015; 9():5397-405. PubMed ID: 26451092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in aqueous vascular endothelial growth factor and pigment epithelium-derived factor after ranibizumab alone or combined with verteporfin for exudative age-related macular degeneration.
    Ahn JK; Moon HJ
    Am J Ophthalmol; 2009 Nov; 148(5):718-724.e1. PubMed ID: 19674731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Photodynamic therapy in combination with ranibizumab versus ranibizumab monotherapy for wet age-related macular degeneration: A systematic review and meta-analysis.
    Su Y; Wu J; Gu Y
    Photodiagnosis Photodyn Ther; 2018 Jun; 22():263-273. PubMed ID: 29753123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. INITIAL VERSUS DELAYED PHOTODYNAMIC THERAPY IN COMBINATION WITH RANIBIZUMAB FOR TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY: The Fujisan Study.
    Gomi F; Oshima Y; Mori R; Kano M; Saito M; Yamashita A; Iwata E; Maruko R;
    Retina; 2015 Aug; 35(8):1569-76. PubMed ID: 25830698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
    Kourlas H; Abrams P
    Clin Ther; 2007 Sep; 29(9):1850-61. PubMed ID: 18035187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal ranibizumab therapy versus photodynamic therapy for idiopathic choroidal neovascularization: a comparative study on visual acuity, retinal and choroidal thickness.
    Shi X; Wei W; Zhang C
    Chin Med J (Engl); 2014; 127(12):2279-85. PubMed ID: 24931242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients.
    Wada I; Oshima Y; Shiose S; Kano K; Nakao S; Kaizu Y; Yoshida S; Ishibashi T; Sonoda KH
    Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1411-1418. PubMed ID: 31119425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Wet form age-related macular degeneration two years treatment results using anti VEGF drugs].
    Studnička J; Rencová E; Dusová J; Marák J; Burova M; Rozsíval P; Jarkovský J; Kandrnal V
    Cesk Slov Oftalmol; 2013 Aug; 69(3):96-101. PubMed ID: 24437955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION WITH RANIBIZUMAB COMBINED WITH KETOROLAC EYEDROPS OR PHOTODYNAMIC THERAPY.
    Semeraro F; Russo A; Delcassi L; Romano MR; Rinaldi M; Chiosi F; Costagliola C
    Retina; 2015 Aug; 35(8):1547-54. PubMed ID: 25784358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularization.
    Kachi I; Yasukawa T; Kato A; Takase N; Morita H; Kubota A; Hirano Y; Uemura A; Ogura Y
    Jpn J Ophthalmol; 2016 May; 60(3):179-86. PubMed ID: 26919844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for neovascular age-related macular degeneration.
    Sivaprasad S; Patra S; DaCosta J; Adewoyin T; Shona O; Pearce E; Chong NV
    Ophthalmologica; 2011; 225(4):200-6. PubMed ID: 21293163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of combination photodynamic therapy with ranibizumab or bevacizumab for treatment of wet age-related macular degeneration.
    Rishi E; Rishi P; Sharma V; Koundanya V; Athanikar R
    Oman J Ophthalmol; 2016; 9(2):87-92. PubMed ID: 27433034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of 1-year visual outcome in OCT analysis comparing ranibizumab monotherapy versus combination therapy with PDT in exsudative age-related macular degeneration.
    Weingessel B; Mihaltz K; Vécsei-Marlovits PV
    Wien Klin Wochenschr; 2016 Aug; 128(15-16):560-5. PubMed ID: 25787216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-year results of photodynamic therapy combined with intravitreal ranibizumab for exudative age-related macular degeneration.
    Nakamura T; Miyakoshi A; Fujita K; Yunoki T; Mitarai K; Yanagisawa S; Fuchizawa C; Hayashi A
    J Ophthalmol; 2012; 2012():154659. PubMed ID: 22174997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
    Brown DM; Michels M; Kaiser PK; Heier JS; Sy JP; Ianchulev T;
    Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.